12th week of 2011 patent applcation highlights part 36 |
Patent application number | Title | Published |
20110071067 | Washing And Cleaning Agent - The invention relates to washing and cleaning agents comprising a combination of chlorophyllase and a further hydrolase, preferably a lipase, particularly a galactolipase. The combination of chlorophyllase and galactolipase improves the cleaning power, particularly for chlorophyll-containing stains, compared to each of the two enzymes alone. | 2011-03-24 |
20110071068 | Subtilases - The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent. | 2011-03-24 |
20110071069 | SHEAR-THINNING, DISPENSABLE LIQUID ABRASIVE CLEANSER WITH IMPROVED SOIL REMOVAL, RINSEABILITY AND PHASE STABILITY - An improved liquid abrasive cleanser is described that shows greatly improved soil removal performance along with improved rinsing characteristics. The improved cleanser is comprised of abrasives, silica, at least one surfactant, an associative polymer thickener, a pH adjusting agent and water. The compositions of the present invention show pseudo-plastic rheology in that they shear thin upon dispensing through a bottle closure, but re-thicken on hard surfaces to provide vertical cling. | 2011-03-24 |
20110071070 | PERFUME COMPOSITION - The present invention relates to a perfume composition as a raw material of fruity perfumes which has a conventionally unknown peculiar fresh, woody, floral, grassy-leafy nuance and is capable of harmonizing with various perfumes to provide perfume preparations having a more sophisticated odor or scent. The perfume composition of the present invention includes a compound represented by the general formula (I): | 2011-03-24 |
20110071071 | PSMB10: A DIAGNOSIS MARKER AND THERAPEUTIC TARGET OF CHRONIC REJECTION - The present invention relates to a method for diagnosing chronic graft rejection of a grafted organ in a subject from a biological sample of said subject, comprising: (a) determining in vitro an expression level value for PSMB10 in said subject biological sample, (b) comparing said value to at least one reference expression level value for PSMB10 in at least one reference sample, and (c) diagnosing if said subject is or not undergoing chronic rejection of said grafted organ. The invention also concerns a diagnostic kit or microarray for performing the method of the invention. The invention further concerns the medical use of proteasome inhibitors for treating chronic rejection. | 2011-03-24 |
20110071072 | Antifungal Bone Cements - Antifungal bone cement compositions and methods of using the same are disclosed. In one aspect, a bone cement composition comprises an echinocandin lipopeptide antifungal agent and a cementing agent. Optionally, the echinocandin lipopeptide antifungal agent is selected from the group consisting of micafungin, caspofungin and anidulafungin. The echinocandin lipopeptide antifungal agent is optionally micafungin. Methods of preventing a fungal infection following an arthroplasty procedure are also provided. | 2011-03-24 |
20110071073 | Detection of mutations in a gene associated with resistance to viral infection, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 2011-03-24 |
20110071074 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS - A deuterated α-ketoamido steric specific compound of the formula | 2011-03-24 |
20110071075 | PROMOTER FOR BICARBONATE SECRETION IN GASTROINTESTINAL TRACT - A substance is described which can prevent or treat a disease associated with the secretion of an acid. A calcium receptor activator is the active ingredient in a composition which promotes bicarbonate secretion in a gastrointestinal tract. Examples of the calcium receptor activator include γ-Glu-X-Gly, wherein X represents an amino acid or an amino acid derivative, γ-Glu-Val-Y, wherein Y represents an amino acid or an amino acid derivative, γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, γ-Glu-Met(O), γ-Glu-γ-Glu-Val, γ-Glu-Val-NH2, γ-Glu-Val-ol, γ-Glu-Ser, γ-Glu-Tau, γ-Glu-Cys(S-Me)(O), γ-Glu-Leu, γ-Glu-Ile, γ-Glu-t-Leu, and γ-Glu-Cys(S-Me). | 2011-03-24 |
20110071076 | NOVEL EXENDIN AGONIST COMPOUNDS - Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would benefit by lower plasma glucose and delaying and/or slowing gastric emptying. | 2011-03-24 |
20110071077 | Thrombopoietic Compounds - The invention relates to the use of compounds, especially peptides or polypeptides, that have thrombopoietic activity, and pegylated forms thereof. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal. | 2011-03-24 |
20110071078 | METHODS FOR TREATING NEUROLOGICAL DEFICITS - The present invention features methods and compositions for treating a patient who has a neurological deficit. The method can be carried out, for example, by contacting (in vivo or in culture) a neural progenitor cell of the patient's central nervous system (CNS) with a polypeptide that binds the epidermal growth factor (EGF) receptor and directing progeny of the proliferating progenitor cells to migrate en masse to a region of the CNS in which they will reside and function in a manner sufficient to reduce the neurological deficit. The method may include a further step in which the progeny of the neural precursor cells are contacted with a compound that stimulates differentiation. | 2011-03-24 |
20110071079 | SELF-ASSEMBLING POLY(DIOL CITRATES)-PROTEIN HYDROGELS - The present invention can be directed to poly(diol-citrate)-based copolymers, compositions thereof comprising protein components and methods of use and assembly. | 2011-03-24 |
20110071080 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 2011-03-24 |
20110071081 | METHODS USEFUL IN THE TREATMENT OF BONE RESORPTION DISEASES - The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months. | 2011-03-24 |
20110071082 | LONG LASTING ANTI-ANGIOGENIC PEPTIDES - Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect. | 2011-03-24 |
20110071083 | Modification of the properties of a fibrin matrix with respect to growth and ingrowth of cells - A method for modifying the properties of a fibrin matrix relative to growth and ingrowth of cells, wherein for forming the fibrin matrix a fibrinogen is used consisting of a selected fibrinogen variant or a fibrinogen enriched or depleted in a selected fibrinogen variant. In particular, the use of high-molecular weight (HMW) fibrinogen leads to a fibrin having accelerated angiogenesis properties, while the use of low-molecular weight (LMW and/or LMW′) fibrinogen leads to fibrin having decelerated angiogenesis properties. The use of HMW fibrinogen when setting up angiogenesis tests results in that the tests require less time. Fibrin sealants on the basis of HMW fibrinogen can be used for burns, to promote wound healing or to inhibit scar tissue. Fibrin sealants on the basis of LMW or LMW′ fibrinogen are useful to inhibit adhesions and tumor growth, for instance after surgical operations. | 2011-03-24 |
20110071084 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS - The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) | 2011-03-24 |
20110071085 | USE OF SURVIVIN TO TREAT KIDNEY FAILURE - The present invention relates generally to methods of for the prevention and treatment for renal disease. In particular, the invention relates to methods of prevention and treatment of mammals, including humans, which are at risk of developing renal failure. This is generally in the field of treatment or prevention of acute renal failure by administration of the anti-apoptotic molecule survivin. The invention also includes the treatment of kidney transplants (renal allografts) to prolong survival of the graft during cold ischemia and immediately after transplantation. | 2011-03-24 |
20110071086 | COMPOSITIONS FOR TISSUE REPAIR/REGENERATION - The invention provides compositions and methods for cardiac repair and/or regeneration of tissues such as myocardium. | 2011-03-24 |
20110071087 | POLYPEPTIDES HAVING MODULATORY EFFECTS ON CELLS - The present invention relates to peptides and polypeptides having the sequence SAVTFAVCAL or variants thereof, capable of binding to Calcineurin and/or to NS5A-TP2 and to their use in therapy, as well as to nucleic acid sequences and vectors encoding these peptides and polypeptides, and to cells comprising said polypeptides, nucleic acid sequences or vectors. The invention further relates to the use of the peptides, polypeptides or their derivatives to bring about phenotypic changes in mammalian cells, particularly to up-regulate calcineurin activity. The invention finally relates to a method for intracellular identification of substances which bind to calcineurin and which modulate the physiological effects of calcineurin. | 2011-03-24 |
20110071088 | METHOD FOR TREATING NEUROLOGICAL DISORDERS - The present invention is based on the discovery that suppressing the activity of the Nogo receptor (NgR) alone does not result in extensive axon regeneration unless the intrinsic growth program of neurons is also activated. Accordingly, the present invention is directed to methods of stimulating axon regeneration using a combination therapy wherein agents that inhibit NgR activity or downstream pathways activated by inhibitory signals are combined with agents that activate the growth pathway of neurons (e.g. polypeptide growth factors, activators of macrophages, purine nucleosides, or hexoses). | 2011-03-24 |
20110071089 | PEPTIDE COMPOSITION FOR CANCER TREATMENT BY INHIBITING TRPV6 CALCIUM CHANNEL ACTIVITY - The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer. | 2011-03-24 |
20110071090 | Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle - A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously. | 2011-03-24 |
20110071091 | INJECTABLE AQUEOUS OPHTHALMIC COMPOSITION AND METHOD OF USE THEREFOR - The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent. | 2011-03-24 |
20110071092 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF - The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell. | 2011-03-24 |
20110071093 | Novel Reagents - Oligomeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble, non-peptidic oligomer and a pharmaceutically active agent. The oligomeric reagents are useful for, among other things, forming oligomer active agent conjugates. Related methods, compositions, preparations, and so forth are also provided. | 2011-03-24 |
20110071094 | (D)-ALLOSE INDUCING PROGRAMMED CELL DEATH IN HORMONE REFRACTORY PROSTATE CANCER LINES - The present disclosure relates allose inducing programmed cell death in hormone refractory prostate cancer cell lines. More particularly, the present disclosure relates to a D-allose inducing programmed cell death in hormone refractory prostate cancer cell line of DU145 in dose-dependent manner by repressing cell growth and inhibiting cell cycle as well as by reducing expression of caspase-3 and poly (ADP-ribose) polymerase (PARP). | 2011-03-24 |
20110071095 | Compositions and Methods for Increasing Telomerase Activity - The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells. | 2011-03-24 |
20110071096 | Macrolides Having Antibiotic Activity - The present invention relates to a semi-synthetic macrolide having antimicrobial activity, in particular antibacterial activity; pharmaceutical compositions comprising the macrolide; and methods of using the macrolide to treat or prevent an infection. | 2011-03-24 |
20110071097 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF - The present invention provides novel cephalotaxus esters, syntheses thereof, and intermediates thereto. The invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of using said compounds or compositions in the treatment of proliferative diseases (e.g., benign neoplasm, cancer, inflammatory disease, autoimmune disease, diabetic retinopathy) and infectious disease. The invention further provides methods of using said compounds or compositions in the treatment of multidrug resistant cancer. | 2011-03-24 |
20110071098 | FLURBIPROFEN AND MUSCLE RELAXANT GEL COMBINATIONS THEREOF - A topical pharmaceutical gel includes flurbiprofen or a pharmaceutically acceptable salt of flurbiprofen, thiocolchicoside or a pharmaceutically acceptable salt of thiocolchicoside, and menthol. Pharmaceutical combinations of flurbiprofen, thiocolchicoside, and menthol in the form of topical gels with anti-inflammatory, analgesic, and myorelaxant activities are described. | 2011-03-24 |
20110071099 | Cationic Ceramides, And Analogs Thereof, And Their Use For Preventing Or Treating Cancer - The present invention relates to cationic ceramides, their dihydro-analogs and aromatic analogs and their derivatives, comprising a pyridinium group. Also provided are methods for making cationic ceramides comprising a pyridinium group, and their use for treating or preventing diseases associated with cell overproliferation and sphingolipid signal transduction, such as cancer, inflammation, and stenosis. The compounds are also useful as mitochondritropic agents that are localized to mitochondria carrying with them chemical cargoes, such as drugs, or signaling molecules, such as fluorophores for probing organelle structure and functions. | 2011-03-24 |
20110071100 | SULFOBETAINES FOR CANCER, OBESITY, MACULAR DEGENERATION, NEURODEGENERATIVE DISEASES - The subject of the invention provides a pharmaceutical composition comprising a sulfobetaine, a sulfobetaine for therapy, uses thereof and methods of treating cancer obesity, age related macular degeneration or neurodegenerative diseases comprising administering a composition comprising a sulfobetaine. | 2011-03-24 |
20110071101 | Nucleoside Phosphonate Analogs - The invention is related to phosphorus substituted nucleoside compounds and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2011-03-24 |
20110071102 | Compositions and Methods to Treat Recurrent Medical Conditions - The invention describes methods and compositions for alleviating recurrent medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction. Representative afflictions include insomnia, erectile dysfunction, female sexual dysfunction, neuropathic pain, attention deficit disorder, and depression. | 2011-03-24 |
20110071103 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects. | 2011-03-24 |
20110071104 | Methods for Treating Osteoarthritis - A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed. | 2011-03-24 |
20110071105 | WOUND-HEALING PHARMACEUTICAL COMPOSITIONS IN THE FORM OF A CREAM BASED ON AMINO ACIDS AND SODIUM HYALURONATE - This invention relates to wound-healing pharmaceutical or cosmetic (anti-skin aging) compositions in the form of a cream based on amino acids and sodium hyaluronate. | 2011-03-24 |
20110071106 | GLYCOSAMINOGLYCAN ORAL USE AND COMPOSITIONS - The present invention concerns the use of a glycosaminoglycan association of hyaluronic acid and chondroitin sulfate for the preparation of oral compositions for the prevention or for the treatment of upper gastro-intestinal tract disorders and for the preparation of upper gastro-intestinal epithelial damage, as well as the oral compositions comprising said glycosaminoglycan association. | 2011-03-24 |
20110071107 | USES OF WATER-SOLUBLE CELLULOSE DERIVATIVES FOR PREVENTING OR TREATING METABOLIC SYNDROME - Water-soluble cellulose derivatives are useful in methods of preventing or treating metabolic syndrome or a symptom or condition associated with the metabolic syndrome in an individual, and in particular for preventing or treating one or more of the symptoms a) hypertension, b) proinflammatory or inflammation state and c) prothrombotic state. | 2011-03-24 |
20110071108 | Beta-Cyclodextrin Derivatives as Antibacterial Agents - The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units. | 2011-03-24 |
20110071109 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTIC AGENTS FOR LYSOSOMAL STORAGE DISORDERS - Embodiments herein relate to the field of lysosomal storage disorders, and, more specifically, to methods of treating lysosomal storage disorders such as Niemann-Pick type C disease, for instance with inhibitors of histone deacetylases, particularly inhibitors of class 1 histone deacetylases. In various embodiments, methods of treating Niemann-Pick type C disease with inhibitors of class 1 histone deacetylases are described. | 2011-03-24 |
20110071110 | Water Dispersible Policosanol Cyclodextrin Complex and Method of its Production - Disclosed is a formulation of policosanol with natural cyclodextrins resulting in a water dispersible form of policosanol. The disclosed process provides an economical commercial method for making the policosanol complex. The complex is suitable for incorporation into oral dosage forms and also in functional foods. One aspect of the present disclosure is a process for making a water dispersible policosanol cyclodextrin complex for animal ingestion. This method includes preparing a policosanol cyclodextrin complex and administering said complex to an animal. The preferred animal is a human with the route of administration being oral ingestion. The form of the complex for ingestion can be a hard gelatin capsule, tablet or wafers, which may contain other ingredients, both active and inactive. The complex also can be further formulated with excipients suitable for soft gelatin capsules, such as, for example, vegetable oils, waxes, lecithin, and surfactants such as Tween-80. | 2011-03-24 |
20110071111 | CICLETANINE IN COMBINATION WITH ORAL ANTIDIABETIC AND/OR BLOOD LIPID-LOWERING AGENTS AS A COMBINATION THERAPY FOR DIABETES AND METABOLIC SYNDROME - Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and an oral antidiabetic agent for treating and/or preventing complications (including microalbuminuria, nephropathies, retinopathies and other complications) in patients with diabetes or metabolic syndrome. | 2011-03-24 |
20110071112 | Compositions and Methods for Preserving Colors and Patterns of Plants - The present invention relates to a composition for preserving plants, which comprises 5 carbon alcohol, at least one alcohol selected from the group consisting of 3 carbon alcohol and 4 carbon alcohol, a thiourea and at least one acid selected from the group consisting of tartaric acid and boric acid. The composition is used to preserve colors, patterns and DNA of plants. The composition can also be used to change colors of flowers. The present invention also relates to a method for preserving plants, which comprises soaking the plants in the composition of the present invention. | 2011-03-24 |
20110071113 | Thiazole Derivatives and Use Thereof - The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 2011-03-24 |
20110071114 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS USING CEFTAROLINE - The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil). | 2011-03-24 |
20110071115 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS - The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, infections, and certain immunological disorders. | 2011-03-24 |
20110071116 | ANTIMICROBIAL N-HALOGENATED AMINO ACID SALTS - The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens. | 2011-03-24 |
20110071117 | COMBINATIONS OF ANTIOXIDANTS AND ANTI-INFLAMMATORY DRUGS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Disclosed herein are compositions comprising 5-aminosalicylic acid (5-ASA), or a pharmaceutically acceptable salt thereof and an antioxidant, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating an inflammatory bowel disease in a subject, reducing cytokine gene expression in colonic tissue of a subject, and reducing myeloperoxide activity in colonic tissue of a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising 5-ASA, or a pharmaceutically acceptable salt thereof, and an antioxidant, or a pharmaceutically acceptable salt thereof. | 2011-03-24 |
20110071118 | Methods of Making Compositions Comprising Lecithin Oils and NSAIDS for Protecting the Gastointestinal Tract and Providing Enhanced Therapeuitc Activity - A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulstion for internal, oral, direct or topical administration. | 2011-03-24 |
20110071119 | HEAT RESISTANT DELIVERY SYSTEM - A heat resistant chewable composition for the oral delivery of dietary supplements and pharmaceutical compounds. The chewable composition includes a delivery vehicle and an active ingredient incorporated therein. The delivery vehicle may include a gummy candy made from a binding agent with thermo-irreversible characteristics. The active ingredient may include an over-the-counter drug or a prescription drug to provide a desired effect on the user. The active ingredient may also include any combination of nutraceuticals, vitamins, minerals, antioxidants, soluble and insoluble fiber, herbs, plants, amino acids, probiotics, prebiotics, fatty acids, digestive enzymes, or any other health promoting ingredient. | 2011-03-24 |
20110071120 | SOLID STATE FORMS OF TAPENTADOL SALTS - Provided herein are novel solid state forms of tapentadol salts, process for their preparation, pharmaceutical compositions, and method of treating thereof. The tapentadol salts include an L-(−)-camphorsulfonate salt, a dibenzoyl-(L)-tartrate salt, a dibenzoyl-(D)-tartrate salt, a malate salt, a maleate salt, or a salicylate salt. | 2011-03-24 |
20110071121 | DIAGNOSIS AND/OR PROGNOSIS OF RENAL DYSFUNCTION - The present invention relates to a method for diagnosing and/or prognosing renal dysfunction. The method comprises the steps of:—(a) determining the level of an anti-inflammatory cytokine present in a urine sample from a subject prior to physical trauma, prior to a hypotensive event, prior to sepsis, and/or prior to septic shock syndrome; (b) determining the level of the anti-inflammatory cytokine present in a urine sample from the subject following physical trauma, following or during a hypotensive event, following or during sepsis, and/or following or during septic shock syndrome; (c) calculating the difference between the level of the anti-inflammatory cytokine determined in step a) from the level of the anti-inflammatory cytokine determined in step b), and (d) providing a diagnosis and/or prognosis on the basis of a comparison between the difference calculated in step c) and the difference calculated in step c) when steps a) and b) are practiced on a control group. | 2011-03-24 |
20110071122 | System for use by compounding pharmacists cists to produce hormone replacement medicine customized for each customer - This invention provides a system for compounding a pharmaceutical product for hormone replacement therapy. The system has a set of concentrated reagent compositions, each containing one or more steroid hormones dissolved in one or more solvents. The needs of each consumer are ascertained, and a pharmaceutical product is compounded for them using the concentrated reagent compositions. Each product has a custom tailored combination of steroid hormones at a concentration that is therapeutically effective for the consumer in accordance with their needs. | 2011-03-24 |
20110071123 | Noninvasive Method for Measuring Histamine From Skin as an Objective Measurement of Itch - A method for measuring of histamine in an epidermis comprising applying an adhesive article to an epithelium of a mammal; allowing for adherence of epithelial cells to the adhesive article; removing the adhesive article from the epithelium of the mammal; preparing the adhesive article using standard laboratory methods for extraction; extracting histamine from the epithelial cells adhered to said adhesive article; measuring histamine from the epithelial cells adhered to said adhesive article; determining the amount of histamine in the epithelial cells as compared to a baseline sample. Further, a method of objectively measuring the perception of itch in mammals and wherein there is a reduction in histamine from a baseline level which is directly proportional to a reduction in an itch perception. | 2011-03-24 |
20110071124 | Compounds that Inhibit Production of sAPPB and AB and Uses Thereof - The present invention relates to compounds with activity as inhibitors of sAPPβ and Aβ production, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease and pharmaceutical compositions containing such candidate compounds. | 2011-03-24 |
20110071125 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY - This invention relates to novel substituted phenylamino-benzene compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. | 2011-03-24 |
20110071126 | INHIBITORS OF BETA-SECRETASE - The present invention is directed to a compound represented by the following structural formula | 2011-03-24 |
20110071127 | Compounds Which Modulate the CB2 Receptor - Compounds of formula (I) | 2011-03-24 |
20110071128 | NOVEL IMIDAZOPYRIDINES - The invention is concerned with novel imidazopyridine derivatives of formula (I) | 2011-03-24 |
20110071129 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE - [Problem] To provide a melanin concentrating hormone receptor antagonist useful as medicines for central system disorders, cardiovascular disorders, metabolic disorders. | 2011-03-24 |
20110071130 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES - The invention relates to 2-aminobenzimidazoles useful in treating disorders that are mediated by A | 2011-03-24 |
20110071131 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands - The present invention provides compounds of Formula (I): | 2011-03-24 |
20110071132 | SUBSTITUTED OXINDOLE DERIVATIVES, DRUGS CONTAINING SAID DERIVATIVES AND THE USE THEREOF - The invention relates to novel oxindol derivative of general formula (I), wherein substituents R | 2011-03-24 |
20110071133 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS - Bicyclic aryl substituted triazoles or heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed. | 2011-03-24 |
20110071134 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRIMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES - A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role: | 2011-03-24 |
20110071135 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA - There is described a method for increasing the maximal tolerated close and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT | 2011-03-24 |
20110071136 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS - The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders. | 2011-03-24 |
20110071137 | PROCESS FOR PREPARING SUSTAINED RELEASE TABLETS - The present invention relates to a novel process for preparing sustained release tablets containing medicinal compounds and the products prepared by said process. The present invention is directed to a method of preparing a sustained release pharmaceutical composition having a predetermined drug release profile, but which is deviated therefrom by adding a tableting effective amount of a water insoluble or partially insoluble cellulose, to said pharmaceutical composition comprised of a drug in a therapeutically effective amount, and sustained release carrier present in amounts effective retard the release of the drug from the pharmaceutical composition and said cellulose, the latter being present in an aqueous system, the improvement comprising adding to the composition an effective amount of maltodextrin to retard the increase on the rate of release of the drug from the addition of said cellulose thereto. | 2011-03-24 |
20110071138 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PREMATURE EJACULATION - The present invention provides an oral pharmaceutical composition for the treatment of premature ejaculation, and the composition provides the effective and excellent treatment of premature ejaculation as well as reduced side effects like nausea, vomiting, drowsiness, sedation effect, awakening effect, and weight-loss etc. | 2011-03-24 |
20110071139 | Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 - This invention relates to novel compounds of the Formula (I), any of the formulas I | 2011-03-24 |
20110071140 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 2011-03-24 |
20110071141 | Pesticidial Condensed-Ring Aryl Compounds - Condensed-ring aryl compounds of formula (I) and use of the same as a agrochemical for controlling noxious organisms wherein (X) | 2011-03-24 |
20110071142 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES - The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor. The present invention also relates to various compounds described herein (e.g., a compound of Formula XI), their pharmaceutically acceptable salts and to methods of using said compounds as described herein. | 2011-03-24 |
20110071143 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS - Compounds of the formula I: | 2011-03-24 |
20110071144 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The invention relates to quinazoline derivatives of formula (1) | 2011-03-24 |
20110071145 | Raf Modulators And Methods Of Use - The present invention relates to compounds of the Formula I, wherein G, A, X1, X2, X3, Z, E, Y, and X are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Raf. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention. | 2011-03-24 |
20110071146 | 17BetaHSD Type 5 Inhibitor - To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5. | 2011-03-24 |
20110071147 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES - Disclosed are novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides, and their pharmaceutically acceptable salts and esters, that are selective inhibitors of KDR and/or FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular solid cancerous tumors of the breast, colon, lung and prostate. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer using these compounds. | 2011-03-24 |
20110071148 | COMPOUNDS AS THE ESTROGEN RELATED RECEPTORS MODULATORS AND THE USES THEREOF - The compounds according to formula VIII, their pharmaceutically acceptable acid or base addition salts, and the uses thereof is disclosed. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for the preparing a medicament for modulating estrogen related receptor (ERR), and treating metabolic diseases, such as high blood fat, fatty liver, hyperglycemia, diabetes, obesity, etc. The definition of the groups of the formula is defined as the description. | 2011-03-24 |
20110071149 | SELECTIVE KINASE INHIBITORS - The present invention relates to methods of modulating (for example, inhibiting) activity of JAK3, comprising contacting the JAK3 with a compound of Formula I: | 2011-03-24 |
20110071150 | INDOLE DERIVATIVES AS CRAC MODULATORS - Compounds of the formula I: | 2011-03-24 |
20110071151 | ABT-263 CRYSTALLINE FORMS - ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2011-03-24 |
20110071152 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS - Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders. | 2011-03-24 |
20110071153 | DIHYDROPYRAZOLE DERIVATIVES AS TYROSINE KINASE MODULATORS FOR THE TREATMENT OF TUMORS - Compounds of the formula I, in which R | 2011-03-24 |
20110071154 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS - The present invention is concerned with novel sulfonamides of formula I | 2011-03-24 |
20110071155 | Tricyclic Nitrogen Containing Compounds And Their Use As Antibacterials - Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof: | 2011-03-24 |
20110071156 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM - The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R | 2011-03-24 |
20110071157 | Role of N-2-Hydroxy-Ethyl-Piperazine-N'-2-Ethane Sulfonic Acid (HEPES) in Pain Control and Reversal of Demyelinization Injury - Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents. | 2011-03-24 |
20110071158 | NEW COMPOUNDS - The present invention encompasses compounds of general formula (1) | 2011-03-24 |
20110071159 | 6- (4-CYCLOPROPYLPIPERAZIN-1-YL) -2 ' -METHYL- [3, 4 ' ] -BIPYRIDINE AND ITS USE AS A MEDICAMENT - 6- (4-Cyclopropylpiperazin-1-yl) -2′-methyl- [3, 4′]bipyridinyl and salts and hydrates thereof interact with the histamine H3 receptor are defined. | 2011-03-24 |
20110071160 | 1,3-DIHYDRO-2H-PYRROLO[3,2-b]PYRIDIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF - The subject matter of the present invention are compounds corresponding to formula (I): | 2011-03-24 |
20110071161 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to the triazolopyridine carboxamide derivatives of general formula (I): | 2011-03-24 |
20110071162 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The disclosure relates to the triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives of general formula (I): | 2011-03-24 |
20110071164 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS - This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers. | 2011-03-24 |
20110071165 | Aza- and polyazanthranyl amides and their use as medicaments - Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides. | 2011-03-24 |
20110071166 | MEDICINE CONSISTING OF CONCOMITANT USE OR COMBINATION OF DPP-IV INHIBITOR AND OTHER DIABETIC MEDICINE - The problem to be solved by the present invention is to provide a medicine which is excellent in the treatment of type 2 diabetes, diabetic complications or impaired glucose tolerance. The present invention provides a medicine characterized in that a compound represented by the following general formula (I), a salt thereof, or a solvate thereof, and at least one kind of other diabetic medicine: | 2011-03-24 |
20110071167 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) - The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions. | 2011-03-24 |